XAV939, a tankyrase 1 inhibitior, promotes cell apoptosis in neuroblastoma cell lines by inhibiting Wnt/β-catenin signaling pathway
© Tian et al.; licensee BioMed Central Ltd. 2013
Received: 4 May 2013
Accepted: 4 November 2013
Published: 5 December 2013
Neuroblastoma (NB) is the most common extracranial solid tumor in childhood. The present treatment including surgery, chemotherapy and radiation, which have only 40% long-term cure rates, and usually cause tumor recurrence. Thus, looking for new effective and less toxic therapies has important significance. XAV939 is a small molecule inhibitor of tankyrase 1(TNKS1). The objective of this study is to investigate the effect of XAV939 on the proliferation and apoptosis of NB cell lines, and the related mechanism.
In the present study, we used both XAV939 treatment and RNAi method to demonstrate that TNKS1 inhibition may be a potential mechanism to cure NB. MTT method was used for determining the cell viability and the appropriate concerntration for follow-up assays. The colony formation assay, Annexin V staining and cell cycle analysis were used for detecting colony forming ability, cell apoptosis and the percentage of different cell cycle. The Western blot was used for detecting the expression of key proteins of Wnt/ beta-catenin (Wnt/β-catenin) signaling pathway.
The results showed that TNKS1 inhibition decreased the viability of SH-SY5Y, SK-N-SH and IMR-32 cells, induced apoptosis in SH-SY5Y as well as SK-N-SH cells, and led to the accumulation of NB cells in the S and G2/M phase of the cell cycle. Moreover, we demonstrated TNKS1 inhibition may in part blocked Wnt/β-catenin signaling and reduced the expression of anti-apoptosis protein. Finally, we also demonstrated that TNKS1 inhibition decreased colony formation in vitro.
These findings suggested that TNKS1 may be a potential molecule target for the treatment of NB.
KeywordsNeuroblastoma Tankyrase 1 Wnt signaling XAV939
Neuroblastoma (NB) is the most common extracranial solid tumor in childhood and infancy, which is an embryonic tumor of the postganglionic sympathetic nervous system. It remains an important pediatric problem because it accounts for 8–10% of all childhood cancers and for approximately 15% of cancer deaths in children [1–3]. It is associated with poor prognosis because of its ability to regress spontaneously, transform, or show aggressive behavior . Current treatment for high-risk NB consists of a coordinated sequence of chemotherapy, surgery, and radiation [5, 6]. Even with this aggressive treatment, less than 40% of children are likely to achieve long-term cure [5–7]. After that the patients usually underwent tumor recurrence as well as long-term complications following high-dose chemotherapy [8, 9]. There is an urgent need for more effective and less toxic therapies, and molecular target-directed drugs are potential representation.
The evolutionarily conserved Wnt/beta-catenin (Wnt/β-catenin) pathway, which is well-described and canonical, is related to human birth defects, cancer, and other diseases . Wnt signal pathway is one of the fundamental mechanisms that regulate cell proliferation, cell polarity and cell differentiation during embryonic development . As a result, inappropriate regulation of Wnt signaling occurs in several types of cancer, including colon, liver and brain tumors of neuroectodermal origin . Whether the Wnt/β-catenin pathway is activated or not depends on the stability of β-catenin in the cytoplasm. β-catenin is regulated by a destruction complex, which is composed of the scaffolding protein Axin, the tumor suppressor adenomatous polyposis coli gene product (APC), casein kinase 1, and glycogen synthase kinase 3(GSK3). In the absence of Wnt stimulation, β-catenin is phosphorylated by the complex and degraded by the ubiquitination/proteasome pathway. In the presence of Wnt, the Axin-mediated β-catenin phosphorylation can be inhibited, then, accumulated β-catenin enters the nucleus and binds to the TCF/LEF family of DNA-binding factors for activation of Wnt pathway-responsive gene transcription, such as cyclin D1, c-myc, axin2 and so on [10, 12]. Inhibition of Wnt signaling has become an attractive strategy for cancer therapeutics .
An exciting study published recently in Nature , together with an earlier one , has verified a new class of small molecule inhibitors, XAV939, which could block Wnt signaling in colon cancer cell lines by binding to tankyrase (TNKS) catalytic poly-ADP-ribose polymerase (PARP) domain, and then resulted in dramatic stabilization of the Axin protein, thereby lead to increased β-catenin destruction. As a major member of the TNKS family, it has been reported that tankyrase 1(TNKS1) were up-regulated in a variety of cancers, including multiple myeloma, plasma cell leukemia, high-grade non-Hodgkin’s lymphomas, breast cancer, colon cancer, and bladder cancer [16–22]. These reports suggested that TNKS1 played a role in tumor progression. Recently, Bao R et al. demonstrated that XAV939 or siRNA-mediated abrogation of TNKS expression increases Axin1 and Axin2 protein levels and attenuates Wnt-induced transcriptional responses in several breast cancer lines . In our previous studies, we have known that TNKS1 was also up-regulated in NB SH-SY5Y cells (data not shown). It has also been reported that the β-catenin has a close relationship with the prognosis of NB. The stronger the β-catenin expressed in nucleus, the higher risk of NB would be, and the worse the prognosis was . However, whether the proliferation of NB cell lines could be inhibited through blocking the Wnt pathway or other mechanisms?
In the present study, we have investigated the anti-proliferative effect of XAV939 on the human NB cell lines. In addition, we studied the cell apoptosis induced by XAV939 and assessed the role of Wnt signaling in it.
Materials and methods
Cell culture and TNKS1 inhibitor
Human NB SH-SY5Y, SK-N-SH and IMR-32 cells were obtained from the American Type Culture Collection (ATCC; Rockville, USA). Cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM; Hyclone), with 10% fetal bovine serum (FBS; Gibco) and 1% penicillin/streptomycin (Sigma Chemical Co., St Louis, Missouri) and were grown in a 5% CO2 incubator at 37°C. The TNKS1 inhibitor XAV939 was purchased from Sigma Aldrich.
Assessment of cellular viability
Cellular viability was assessed by MTT method. Briefly, equal numbers of NB SH-SY5Y, SK-N-SH and IMR-32 cells were plated at a density of 1 × 104 per well in 96-well plates, and were treated with various concentrations of XAV939 for 24, 48, or 72 h. 20 μl MTT (5 mg/ml) were incubated with cells of each sample for 4 h, then were replaced with 150 μl DMSO and 96-well plates were rotated gently for 10 min. Cell viability was determined by measuring colorimetric absorbance at 490 nm, and was read with a microplate reader . Experiments were done in triplicate and average activity rates relative to control and standard errors were calculated.
Colony formation assay
Colony formation assays were performed as described . Briefly, SH-SY5Y cells were plated in triplicate at 100 cells per well in 6-well plates and cultured in DMEM medium supplemented with 10% FBS. After 4-5 h, cells were treated with DMSO or XAV939, as well as transfected with lentivirus-mediated scrambled-shRNA (SCR group) or TNKS1-shRNA (shRNA group). Colonies were allowed to form for 14 days and fixed in methanol for 15 minutes, and dyed with crystal violet for 15 minutes at room temperature. Afterward, the dye was washed off and colonies that contained more than 50 cells were counted. The colony formation efficiency was the ratio of the colony number to the planted cell number.
Apoptosis was measured using Annexin V/FITC Apoptosis Detection kit (KeyGEN Biotech, Nanjing, China) following the manufacturer’s protocol. Briefly, equal numbers of SH-SY5Y and SK-N-SH cells, treated with DMSO or XAV939 for 24, 48, or 72 h, were incubated with Annexin V-FITC, followed by staining of their DNA with propidium iodide (PI) in the dark. Then, each sample was analyzed by fluorescence-activated cell sorting (FACS) (BD, San Jose, CA, USA). The percentages of cells staining positive for Annexin V were calculated, and means as well as standard error were plotted. Alternatively, apoptosis was also determined using Hoechst 33342 staining. After treatment, cells were washed with PBS and stained with Hoechst 33342 (10 μg/mL, Sigma Aldrich). Then the cells were observed by fluorescent microscope (Olympus Inverted Fluorescence Microscope, I × 71) with excitation at 340 nm and approximately 100 cells from five random microscopic fields were counted. The percentage of apoptotic cells was calculated as the ratio of apoptotic cells to total cells. Mean and standard error were calculated for each time point and treatment group.
Cell cycle analysis
Equal numbers of SH-SY5Y, SK-N-SH and IMR-32 cells were plated in 10 cm dishes and treated with DMSO or XAV939 for 24, 48, or 72 h. 106 cells were trypsinized, fixed with 70% ethanol, and incubated over night at 4°C, then were incubated in 100 μl RNase at 37°C for 30 min, followed by staining of their DNA with 400 μl PI for 30 min in the dark, and analyzed by FACS. The average percentages of cells in G0/G1, S or G2/M phases of the cell cycle were quantified and standard error was calculated for three experiments.
Equal numbers of SH-SY5Y and SK-N-SH cells were plated on 10 cm dishes and treated with DMSO or XAV939 for 24, 48 or 72 h. Then the cells were lysed with RIPA buffer and protein concentration was determined by the Bradford method. Equal amounts of protein (40 μg) were used for Western blot analysis with antibodies to anti-β-catenin (Santa Cruz, sc-7199), anti-Cyclin D1 (Santa Cruz, sc-718), anti-c-Myc (Santa Cruz: sc-789) and anti-Bcl-2 (Santa Cruz, sc-492). Specific antibody binding was detected by horseradish peroxidase-conjugated goat anti-rabbit antibodies and visualized with ECL reagent (Santa cruz) according to the manufacturer’s protocol. Antibody to actin was used to evaluate protein loading in each lane.
Silencing of TNKS1 with shRNA
To identify shRNA sequences could knockdown TNKS1 in SH-SY5Y and SK-N-SH cells, we screened three MISSION shRNA clones NM_003747 (GENECHEM CO., LTD., Shanghai, China) targeted against the human TNKS1 sequence. MISSION shRNA clones together with packaging and envelope plasmids GV118 (GENECHEM CO., LTD., Shanghai, China), were transfected into HEK 293 T packaging cells using Lipofectamine 2000 (Invitrogen). At 48 h post-transfection, virus-containing media was used to infect NB cell lines. GFP was used to monitor the efficiency of HEK 293 T transfection and infection. After selection with puromycin (5 μg/ml) for 48 h, cells were tested for TNKS1 expression by qRT-PCR and then used for clonogenic survival assays and Western blot analyses.
The results were presented as Mean ± Standard deviation (S.D.) of triplicate determinations. The data were processed using the Statistical Package for the Social Sciences, version 16.0 (SPSS Inc., Chicago, IL, USA). One-way ANOVA was performed for comparison between different groups. Dunnett’s t (when homogeneity of variances existed) or Dunnett T3 (when heterogeneity of variances existed) was calculated. A P-value of < 0.05 was regarded as statistically significant difference.
TNKS1 inhibition decreases cell growth and proliferation in NB cell lines
TNKS1 inhibition reduces SH-SY5Y cell survival
TNKS1 inhibition induces apoptosis in NB cell lines
TNKS1 inhibition induces the accumulation of NB cell lines at G2/M
TNKS1 inhibition reduces the expression of anti-apoptotic proteins
NB is the most common malignancy of infancy and constitutes 50% of all infantile cancers. NB with higher-grade are quite aggressive and have low cure rates even with combined modality treatments of surgery, radiation and chemotherapy . Understanding the molecular mechanism of NB could help us find key targets which could be exploited efficiently for therapy.
TNKS is a member of the PARP family, which uses NAD + as a substrate to generate ADP-ribose polymers onto target proteins, and results in a post-translational modification referred to as PARsylation . TNKS1 was previously identified as a binding partner for telomerase repeat binding factor 1 (TRF1), which is an important player in the regulation of telomere length at the chromosome ends. It has been shown that TNKS1 expression is up-regulated in several human cancers, and correlates significantly with highly aggressive disease and poor prognosis in some types of cancer, such as breast, colon, and bladder cancer [19–21]. Thus, TNKS1 could be potential therapeutic target for the treatment of malignant NB that overexpressing TNKS1. XAV939, a TNKS1 inhibitor, is synthetized using a chemical genetics approach, and reported to have been used against cancers like colorectal cancers [14, 15] and WTK1 human lymphoblastoid cells . However, the antagonism of XAV939 has not been well studied in NB. In the present study we show that inhibition of TNKS1 either by small molecule inhibitor XAV939 or by a specific shRNA decreases the cell viability of NB cell lines (Figure 1). This phenomenon can be explained by induction of apoptosis (Figure 3) or cell cycle arrest (Figure 4).
Furthermore, we assessed the effects of TNKS1 inhibition on cell survival and proliferation in SH-SY5Y and SK-N-SH cells. It has been reported that inhibition of TNKS1 leading to decreased levels of β-catenin by stabilizing Axin and turning off Wnt/β-catenin signaling [14, 33]. We showed that SH-SY5Y cells treated with XAV939 induces disaggregation of β-catenin compared to untreated controls (Figure 5), indicating that TNKS1 inhibition leads to degradation of β-catenin. We also found that the downstream target proteins of β-catenin, such as Cyclin D1 and c-Myc, were down-regulated, which demonstrated that Wnt/β-catenin signaling was inhibited. We know that high β-catenin/TCF activity is able to drive cell proliferation during tumor formation by turning on the cell-cycle regulator Cyclin D1 , and c-Myc serves as important role in prognosis of NB . The Bcl-2 family of proteins plays a key role in regulation of mitochondrial permeability during apoptosis via intrinsic pathway. In our present study we showed that inhibition of TNKS1 with XAV939 reduced Bcl-2 proteins in SH-SY5Y cancer cells (Figure 5) consistent with the promotion of apoptosis.
Moreover, TNKS1 has been shown to regulate sister telomere separation  and mitotic progression . However, there are some glaring discrepancies between the results of Huang et al. and earlier studies on TNKS1 function during mitosis. Huang et al. found that small molecule drug XAV939 didn’t cause mitotic arrest in DLD-1 colon cancer cells, neither RNAi-TNKS1 do. The results were in sharp contrast with other studies [28, 29, 31]. In the present study we also found that the three NB cell lines, when treated with XAV939, have a prolonged S phase followed by a G2/M cell cycle arrest compared to untreated cells. This discrepancy may be related to different types of cancer and need to be further investigated.
Recently it has been shown that XAV939 inhibits DLD-1 colony formation in an axin-dependent manner . Axin is a concentration-limiting factor in the β-catenin degradation complex and may function more generally as a signal ‘integrator’ in modulating Wnt pathway activity. In our studies, XAV939 as well as shRNA for TNKS1 inhibited SH-SY5Y colony formation in vitro (Figure 2). In conclusion, the present data and previous studies indicate that small molecule inhibitors XAV939 could inhibit the proliferation and colony formation of SH-SY5Y cells by inhibiting TNKS1 might in part through Wnt/β-catenin signaling. But the results are required to be validated in vivo to get a better understanding of the mechanisms involved and the potential role of XAV939 in NB treatment. Moreover, TNKS1 is a protein that participates in both telomere regulation and Wnt/β-catenin signaling, which are essential factors for tumor remedy and recurrence. However, the relationship between the telomere regulation and Wnt/β-catenin signaling need to be further explored. The research will pave the way for NB treatment used by TNKS1 inhibitors.
In sum, we have shown that inhibition of TNKS1 by XAV939 or RNAi method inhibits the proliferation and induces apoptosis of NB cell lines. One of the related mechanisms may be the inhibiting of Wnt/β-catenin signaling. But more experiments should be carried out to clarify the exact mechanisms. This effect would be expected to promote small molecule targeted therapy in patients with malignant NB.
The study was supported by National Natural Science Foundation of China (30772215). The authors would like to thank Professor Yuhua Chen and Xining Pang of Departnzent of Developmental Biology in China Medical University, and people who help us.
- Maris JM, Matthay KK: Molecular biology of neuroblastoma. J Clin Oncol. 1999, 17: 2264-2279.Google Scholar
- Maris JM, Hogarty MD, Bagatell R, Cohn SL: Neuroblastoma. Lancet. 2007, 369: 2106-2120.View ArticleGoogle Scholar
- Sharp SE, Gelfand MJ, Shulkin BL: Pediatrics: diagnosis of neuroblastoma. Semin Nucl Med. 2011, 41: 345-353.View ArticleGoogle Scholar
- Bilir A, Erguven M, Yazihan N, Aktas E, Oktem G, Sabanci A: Enhancement of vinorelbine-induced cytotoxicity and apoptosis by clomipramine and lithium chloride in human neuroblastoma cancer cell line SH-SY5Y. J Neurooncol. 2010, 100: 385-395.View ArticleGoogle Scholar
- Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP: Treatment of high-risk Neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer group. N Engl J Med. 1999, 341: 1165-1173.View ArticleGoogle Scholar
- Pearson AD, Pinkerton CR, Lewis IJ, Imeson J, Ellershaw C, Machin D, European Neuroblastoma Study Group, Children’s Cancer and Leukaemia Group (CCLG formerly United Kingdom Children’s Cancer Study Group): High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 Neuroblastoma: a randomised trial. Lancet Oncol. 2008, 9: 247-256.View ArticleGoogle Scholar
- Zage PE, Kletzel M, Murray K, Marcus R, Castleberry R, Zhang Y, London WB, Kretschmar C: Outcomes of the POG 9340/9341/9342 trials for children with high-risk Neuroblastoma: a report from the Children’s oncology group. Pediatr Blood Cancer. 2008, 51: 747-753.View ArticleGoogle Scholar
- Lau L, Tai D, Weitzman S, Grant R, Baruchel S, Malkin D: Factors influencing survival in children with recurrent neuroblastoma. J Pediatr Hematol Oncol. 2004, 26: 227-232.View ArticleGoogle Scholar
- Laverdière C, Cheung NK, Kushner BH, Kramer K, Modak S, LaQuaglia MP, Wolden S, Ness KK, Gurney JG, Sklar CA: Long-term complications in survivors of advanced stage neuroblastoma. Pediatr Blood Cancer. 2005, 45: 324-332.View ArticleGoogle Scholar
- Clevers H: Wnt/beta-catenin signaling in development and disease. Cell. 2006, 127: 469-480.View ArticleGoogle Scholar
- Logan CY, Nusse R: The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004, 20: 781-810.View ArticleGoogle Scholar
- MacDonald BT, Tamai K, He X: Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009, 17: 9-26.View ArticleGoogle Scholar
- Barker N, Clevers H: Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov. 2006, 5: 997-1014.View ArticleGoogle Scholar
- Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, Charlat O, Wiellette E, Zhang Y, Wiessner S, et al: Tankyrase inhibition stabilizes axin and antagonizes Wnt sianaling. Nature. 2009, 461: 614-620.View ArticleGoogle Scholar
- Chen B, Dodge ME, Tang W, Lu J, Ma Z, Fan CW, Wei S, Hao W, Kilgore J, Williams NS, et al: Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol. 2009, 5: 100-107.View ArticleGoogle Scholar
- Xu D, Zheng C, Bergenbrant S, Holm G, Björkholm M, Yi Q, Gruber A: Telomerase activity in plasma cell dyscrasias. Br J Cancer. 2001, 84: 621-625.View ArticleGoogle Scholar
- MacNamara B, Wang W, Chen Z, Hou M, Mazur J, Gruber A, Porwit-MacDonald A: Telomerase activity in relation to pro- and anti-apoptotic protein expression in high grade non-Hodgkin’s lymphomas. Haematologica. 2001, 86: 386-393.Google Scholar
- Klapper W, Krams M, Qian W, Janssen D, Parwaresch R: Telomerase activity in B-cell non-Hodgkin lymphomas is regulated by hTERT transcription and correlated with telomere-binding protein expression but uncoupled from proliferation. Br J Cancer. 2003, 89: 713-719.View ArticleGoogle Scholar
- Gelmini S, Poggesi M, Distante V, Bianchi S, Simi L, Luconi M, Raggi CC, Cataliotti L, Pazzagli M, Orlando C: Tankyrase, a positive regulator of telomere elongation, is over expressed in human breast cancer. Cancer Lett. 2004, 216: 81-87.View ArticleGoogle Scholar
- Gelmini S, Poggesi M, Pinzani P, Mannurita SC, Cianchi F, Valanzano R, Orlando C: Distribution of tankyrase-1 mRNA expression in colon cancer and its prospective correlation with progression stage. Oncol Rep. 2006, 16: 1261-1266.Google Scholar
- Gelmini S, Quattrone S, Malentacchi F, Villari D, Travaglini F, Giannarini G, Della Melina A, Pazzagli M, Nicita G, Selli C, Orlando C: Tankyrase-1 mRNA expression in bladder cancer and paired urine sediment: preliminary experience. Clin Chem Lab Med. 2007, 45: 862-866.View ArticleGoogle Scholar
- Shervington A, Patel R, Lu C, Cruickshanks N, Lea R, Roberts G, Dawson T, Shervington L: Telomerase subunits expression variation between biopsy samples and cell lines derived from malignant glioma. Brain Res. 2007, 1134: 45-52.View ArticleGoogle Scholar
- Bao R, Christova T, Song S, Angers S, Yan X, Attisano L: Inhibition of tankyrases induces Axin stabilization and blocks Wnt signalling in breast cancer cells. PLoS One. 2012, 7: e48670-View ArticleGoogle Scholar
- Zhi F, Gong G, Xu Y, Zhu Y, Hu D, Yang Y, Hu Y: Activated beta-catenin forces N2A cell-derived neurons back to tumor-like neuroblasts and positively correlates with a risk for human Neuroblastoma. Int J Biol Sci. 2012, 8: 289-297.View ArticleGoogle Scholar
- Mahendroo M, Simpson E, C. Jenkins DM: Exon-specific northern analysis and rapid amplification of cdna ends (race) reveal that the proximal promoter ii (pii) is responsible for aromatase cytochrome p450 (cyp19) expression in human ovary. Mol Cell Endocrinol. 1993, 97: R1-R6.View ArticleGoogle Scholar
- Liang Y, Zhong Z, Huang Y, et al: Stem-like cancer cells are inducible by increasing genomic instability in cancer cells. J Biol Chem. 2010, 285: 4931-4940.View ArticleGoogle Scholar
- Wong RS: Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res. 2011, 30: 87-100.View ArticleGoogle Scholar
- Chang P, Coughlin M, Mitchison TJ: Tankyrase-1 polymerization of poly (ADP-ribose) is required for spindle structure and function. Nat Cell Biol. 2005, 7: 1133-1139.View ArticleGoogle Scholar
- Dynek JN, Smith S: Resolution of sister telomere association is required for progression through mitosis. Science. 2004, 304: 97-100.View ArticleGoogle Scholar
- Maris JM: Recent advances in neuroblastoma. N Engl J Med. 2010, 362: 2202-2211.View ArticleGoogle Scholar
- Hsiao SJ, Smith S: Tankyrase function at telomeres, spindle poles, and beyond. Biochimie. 2008, 90: 83-92.View ArticleGoogle Scholar
- Dregalla RC, Zhou J, Idate RR: Regulatory roles of tankyrase 1 at telomeres and in DNA repair: suppression of T-SCE and stabilization of DNA-PKcs. Aging. 2010, 2: 691-708.Google Scholar
- Waaler J, Machon O, Tumova L, Dinh H, Korinek V, Wilson SR, Paulsen JE, Pedersen NM, Eide TJ, Machonova O, Gradl D, Voronkov A, von Kries JP, Krauss S: A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. Cancer Res. 2012, 72: 2822-2832.View ArticleGoogle Scholar
- Damalas A, Ben-Ze’ev A, Simcha I, et al: Excess beta-catenin promotes accumulation of transcriptionally active p53. EMBO J. 1999, 18: 3054-3063.View ArticleGoogle Scholar
- He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, et al: Identification of c-MYC as a target of the APC pathway. Science. 1998, 281: 1509-View ArticleGoogle Scholar
- Canudas S, Houghtaling BR, Kim JY, et al: Protein requirements for sister telomere association in human cells. EMBO J. 2007, 26: 4867-4878.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.